Maintenance venom immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 4, 2002, Pages 359-362

  Graft, David F ^a  

^a PARK NICOLLET CLINIC   (United States)

Author keywords

Honeybee; Hymenoptera; Venom immunotherapy; Yellow jacket

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G; INSECT VENOM; PREDNISONE; RANITIDINE; TERFENADINE; ALLERGEN; DIAGNOSTIC AGENT;

ANAPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOTHERAPY; INJECTION; INSECT STING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTIBODY SPECIFICITY; DESENSITIZATION; IMMUNOLOGY; INCIDENCE; INSECT BITE; UNITED STATES;

ALLERGENS; ANIMALS; ANTIBODY SPECIFICITY; BEE VENOMS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYMENOPTERA; IMMUNOGLOBULIN G; INCIDENCE; INSECT BITES AND STINGS; UNITED STATES;

EID: 0036675075     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200208000-00011     Document Type: Review

References (29)

1. Graft DF. Venom immunotherapy: indications, selections of venoms, techniques, and efficacy. In: Levine MI, Lockey RL, editors. Monograph on insect allergy. 3rd ed. Pittsburgh. Dave Lambert Associates; 1995. pp. 73-80.
2. Schwartz HJ, Squillace DL, Sher TH, et al. Studies in stinging insect hypersensitivity: Postmortem demonstration of antivenom IgE antibody in possible sting-related sudden death. Am J Clin Pathol 1986; 85:75-78.
3. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 1299:157-161.
4. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072-1080.
5. Schuberth KC, Lichtenstein LM, Kagey-Sobotka A, et al. An epidemiologic study of insect allergy in children. I. Characteristics of the disease. J Pediatr 1982; 100:546-551.
6. Valentine MD. Allergy to stinging insects. Ann Allergy 1993; 70:427-432.
7. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-780.
8. Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109:556-562.
9. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81-86.
10. Nelson BL, Dupont LA, Reid MJ. Prospective survey of local and system reactions to immunotherapy with pollen extracts. Ann Allergy 1986; 56:331-334.
11. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106:840-843. These authors found that the rate of systemic reactions was not different before and after changing protocol to eliminate most dose adjustments for large local reactions.
12. van der Linden PG, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94:151-191.
13. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-535.
14. Müller U, Berchtold E. Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702-709.
15. Graft DF, Reisman RE, Valentine MD, et al. When to start, when to stop and what to measure in venom immunotherapy. J Allergy Clin Immunol 1991; 88:409-413.
16. Golden DBK, Lawrence ID, Kagey-Sobotka A, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386-393.
17. Schwartz HJ, Golden DBK, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990; 85:709-712.
18. Graft DF. Venom immunotherapy during pregnancy. N Engl Reg Allergy Proc 1988; 9:563-565.
19. Kaplan AP, Anderson JA, Valentine MD, et al. J Allergy Clin Immunol 1989; 84:129-130.
20. Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988; 81:1-5.
21. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy [correspondence]. Lancet 1992; 340:908.
22. Reisman RE, Livingston A. Venom immunotherapy: 10 years of experience with administration of single venoms and 50 mg maintenance doses. J Allergy Clin Immunol 1992; 89:1189-1195.
23. Müller UR. Insect sting allergy. Clinical picture, diagnosis and treatment. Stuttgart: Gustav Fischer; 1990.
24. Rüeff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased doses. J Allergy Clin Immunol 2001; 108:1027-1032. This is a clinical report regarding improved results after increasing venom dose in patients who reacted to stings when on the usual dose for maintenance venom immunotherapy.
25. Reisman RE. Insect stings. N Engl J Med 1994; 331:523-527.
26. Kochuyt AM, Stevens EAM. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy. Clin Exp Allergy 1994; 24:35-41.
27. Goldberg A, Confino-Cohen R, Mekori YA. Deliberate bee sting challenge of patients receiving venom immunotherapy at 3-month intervals. J Allergy Clin Immunol 1994; 93:997-1001.
28. Goldberg A, Confino-Cohen R. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol 2001; 107:902-906. This follow-up to their 1994 paper reports on more patients and even studied the outcome of stings after VIT was discontinued in patients who had received 12-week maintenance interval VIT.
29. Graft DF, Golden DBK, Reisman RE, et al. Position Statement. The discontinuation of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1998; 101:573-575.